Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

Rhea-AI Summary

Eagle Pharmaceuticals (OTCMKTS: EGRX) reported results from its 2025 annual meeting held virtually on October 17, 2025. Of 13,157,754 shares outstanding, 10,769,820 shares (≈82%) were present or represented by proxy.

All four director nominees were elected: Class I nominees Michael Graves and Richard Edlin (terms to 2027), and Class II nominees Jennifer Simpson and Luciana Borio (terms to 2028). Broker non-votes totaled 1,064,408. The stockholder vote also ratified BDO USA, P.C. as auditor for fiscal 2025 (FOR 9,011,921; AGAINST 1,700,348; ABSTAIN 57,551).

WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares outstanding as of the record date, 10,769,820 shares, or approximately 82%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

1.   Election of Directors

Election of (i) two Class I nominees for director, Michael Graves and Richard Edlin, to hold office until the 2027 Annual Meeting of Stockholders and (ii) two Class II nominees for director, Jennifer Simpson and Luciana Borio, to hold office until the 2028 Annual Meeting of Stockholders, and, in each case, until his or her successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. Voting results for each director nominee are as set out below:

Nominees:	FOR	WITHHELD
Class I
Michael Graves	8,113,749	1,591,663
Richard Edlin	8,053,759	1,651,653
Class II
Jennifer Simpson	8,102,909	1,602,503
Luciana Borio	8,134,574	1,570,838

Broker Non-Votes: 1,064,408

All nominees were elected.

2.   Appointment of Auditor

Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Voting results are set out below:

FOR	AGAINST	ABSTAIN
9,011,921	1,700,348	57,551

Broker Non-Votes:        -0-

The ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

This press release was published by a CLEAR® Verified individual.

FAQ

What were the turnout and voting figures at Eagle Pharmaceuticals' 2025 annual meeting (EGRX)?

10,769,820 shares were present or represented by proxy out of 13,157,754 outstanding shares, or about 82% turnout.

Who was elected to Eagle Pharmaceuticals' board at the October 17, 2025 annual meeting (EGRX)?

All four nominees were elected: Class I Michael Graves and Richard Edlin (terms to 2027); Class II Jennifer Simpson and Luciana Borio (terms to 2028).

What were the vote counts for each Eagle Pharmaceuticals director nominee (EGRX)?

Michael Graves FOR 8,113,749; Richard Edlin FOR 8,053,759; Jennifer Simpson FOR 8,102,909; Luciana Borio FOR 8,134,574.

Was the appointment of BDO USA as Eagle Pharmaceuticals' auditor ratified (EGRX)?

Yes. The ratification passed with 9,011,921 FOR, 1,700,348 AGAINST and 57,551 ABSTAIN.

How many broker non-votes were recorded at Eagle Pharmaceuticals' 2025 annual meeting (EGRX)?

There were 1,064,408 broker non-votes recorded for director elections.